Effects of rosiglitazone on endothelial function in non-diabetic subjects with metabolic syndrome

To evaluate the effects of rosiglitazone (ROSI), an insulin-sensitizer, on endothelial function and endothelial activation markers in a group of non-diabetic subjects with metabolic syndrome. A group of eighteen subjects (12 women, 6 men), mean age 41.2 +/- 9.7 and BMI 37.8 +/- 6.1 Kg/m2, was treate...

Full description

Saved in:
Bibliographic Details
Published in:Arquivos brasileiros de cardiologia 2006-05, Vol.86 (5), p.366-373
Main Authors: Bahia, Luciana, Aguiar, Luiz Guilherme K, Villela, Nivaldo, Bottino, Daniel, Godoy-Matos, Amélio F, Bouskela, Eliete
Format: Article
Language:Portuguese
Subjects:
Adult
Biomarkers
Cardiovascular Diseases - etiology
Case-Control Studies
Endothelium, Vascular - drug effects
Endothelium, Vascular - physiopathology
Female
Humans
Hypoglycemic Agents - pharmacology
Hypoglycemic Agents - therapeutic use
Inflammation
Male
Metabolic Syndrome - diagnosis
Metabolic Syndrome - drug therapy
Risk Factors
Rosiglitazone
Thiazolidinediones - pharmacology
Thiazolidinediones - therapeutic use
Vasodilation - drug effects
Vasodilator Agents - pharmacology
Vasodilator Agents - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the effects of rosiglitazone (ROSI), an insulin-sensitizer, on endothelial function and endothelial activation markers in a group of non-diabetic subjects with metabolic syndrome. A group of eighteen subjects (12 women, 6 men), mean age 41.2 +/- 9.7 and BMI 37.8 +/- 6.1 Kg/m2, was treated with rosiglitazone 8 mg/day for 12 weeks. Another group of nine healthy subjects, mean age 26.1 +/- 4.4 and BMI 21.7 +/- 1.7 Kg/m2, was studied at baseline to compare vasodilator response. Endothelial function was evaluated by venous occlusion plethysmography after intra-arterial infusions of acetylcholine (Ach) and sodium nitroprusside (SNP). The following were measured: glucose, insulin, lipids, fibrinogen, and high-sensitivity C-reactive protein (CRP). HOMA and Quicki indexes were calculated to quantify insulin resistance (IR). There was an improvement in insulin resistance, as evidenced by lower HOMA-R and higher QUICKI index, as well as a decrease in CRP and fibrinogen levels. Endothelium-dependent vasodilation also improved, as evidenced by greater increment in blood flow after Ach and greater decrement in vascular resistance. No difference in endothelium-independent vasodilation was noted. Rosiglitazone treatment reduced insulin resistance, fibrinogen, and CRP levels and improved endothelial function in non-diabetic subjects with metabolic syndrome. These data suggest that rosiglitazone plays a role in the regulation of endothelial function in patients at high cardiovascular risk.
ISSN:0066-782X
1678-4170